News & Updates

Coming on the heels of the second interim analysis, the protocol-specified final invasive disease-free survival (iDFS) analysis of the phase III NATALEE trial continues to show a highly significant iDFS benefit with the combination of the CDK 4/6 inhibitor ribociclib and a nonsteroidal aromatase inhibitor (NSAI) in individuals with HR+/HER2- early breast cancer.

One in five young BRCA carriers with breast cancer subsequently conceive within 10 years, without any detrimental effect on disease-free survival, according to a study.

In the final overall survival (OS) analysis of the phase III MONARCH 3 trial, the combination of the CDK 4/6 inhibitor abemaciclib and a nonsteroidal aromatase inhibitor (NSAI) continued to show clinically meaningful signals as first-line (1L) treatment for HR+/HER2- advanced breast cancer.

A diet rich in cholesterol during early pregnancy and genetic variations of cholesterol metabolism genes both contribute to the risk of gestational diabetes mellitus (GDM), suggests a study.